nucala® (mepolizumab) mode of action in severe refractory eosinophilic asthma | gsk
Published 3 years ago • 3.9K plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:28
nucala (mepolizumab) - asthma
-
9:14
fda approval of nucala for treatment of severe asthma in children as young as 6
-
8:03
nucala (mepolizumab) autoinjector: how to use
-
6:51
#mepolizumab | uses, dosage, side effects and mechanism | nucala
-
15:25
module 5 treatment mepolizumab reslizumab benralizumab
-
2:19
the importance of eosinophils in personalized severe asthma treatment
-
3:59
mepolizumab: attacking asthma associated with eosinophils
-
7:16
ben’s story | nucala (mepolizumab)
-
7:21
kate’s story | nucala (mepolizumab)
-
3:01
mepolizumab reduces exacerbations and improves asthma control - video abstract [id 298559]
-
9:20
mepolizumab and omalizumab - evidence for use in severe asthma -- bavls
-
4:28
mepalizumab in eosinophilic asthma
-
4:16
linda rogers, ats 2018 – treatment of severe eosinophilic asthma with il-5 antagonists
-
0:53
a new option for severe asthma
-
20:15
nucala
-
1:03
benralizumab mode of action
-
2:59
journal club- pros of switching from omalizumab or mepolizumab to benralizumab in asthma patients
-
1:00
air supply: targeting eosinophils in severe asthma
-
3:07
michael wechsler: how mepolizumab helps egpa patients